FindTrial
Sign In

systemic inflammation in stable COPD patients with positive potential pathongenic microorganisms and the influence of short-term antibiotic therapy for the stable COPD patients of positive potentially pathongenic microorganisms—single center prospective randomized controlled study

systemic inflammation in stable COPD patients with positive potential pathongenic microorganisms and the influence of short-term antibiotic therapy for the stable COPD patients of positive potentially pathongenic microorganisms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006769
Enrollment
Unknown
Registered
2015-07-16
Start date
2015-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Two groups:moxifloxacin versus original treatment

Sponsors

Beijing Luhe Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
80 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Meet the criteria for the diagnosis of chronic obstructive pulmonary disease(COPD): After inhalation of salbutamol, FEV1/FVC<70%, and exclusion of other diseases; 2. 40 years of age or older; 3. Qualified sputum samples can obtained, and sputum culture with positive potential pathogenic microorganisms (PPMs); 4. Signed the informed consent.

Exclusion criteria

Exclusion criteria: Allergic to quinolone; Immunosuppressive therapy; long-term oral corticosteroid; The other medicines treatment have obviously changed during the study; combined with malignancy; Mobile inconvenience.

Design outcomes

Primary

MeasureTime frame
C-reactive protein;interleukin8;fibrinogen;sputum;—

Countries

China

Contacts

Public ContactWANG JINXIANG
wangjx0090@sina.com+86 13911469017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026